Analysts take a look at Celsion Corporation (NASDAQ:CLSN) having this to say.

January 16, 2018 - By Richard Conner

 Analysts take a look at Celsion Corporation (NASDAQ:CLSN) having this to say.

Celsion Corporation (NASDAQ:CLSN) Ratings Coverage

Among 2 analysts covering Celsion (NASDAQ:CLSN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Celsion had 9 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was downgraded by Maxim Group on Thursday, November 10 to “Hold”. The stock of Celsion Corporation (NASDAQ:CLSN) has “Buy” rating given on Monday, November 20 by Oppenheimer. The rating was maintained by Maxim Group on Monday, August 7 with “Hold”. The rating was maintained by Cantor Fitzgerald on Friday, August 7 with “Buy”. The stock has “Hold” rating by Maxim Group on Thursday, June 1. The firm has “Hold” rating by Zacks given on Wednesday, August 12. As per Tuesday, August 15, the company rating was maintained by Maxim Group. The company was upgraded on Thursday, October 5 by Maxim Group. The firm has “Buy” rating given on Tuesday, January 19 by Maxim Group. Below is a list of Celsion Corporation (NASDAQ:CLSN) latest ratings and price target changes.

20/11/2017 Broker: Oppenheimer Rating: Buy New Target: $9.0 Initiate
05/10/2017 Broker: Maxim Group Old Rating: Hold New Rating: Buy Upgrade
15/08/2017 Broker: Maxim Group Rating: Hold Maintain
07/08/2017 Broker: Maxim Group Rating: Hold Maintain

The stock increased 1.45% or $0.04 during the last trading session, reaching $2.79. About 13,244 shares traded. Celsion Corporation (NASDAQ:CLSN) has declined 82.71% since January 16, 2017 and is downtrending. It has underperformed by 99.41% the S&P500.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company has market cap of $44.81 million. The companyÂ’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It currently has negative earnings. It is also developing GEN-1, a DNA immunotherapeutic product for the localized treatment of ovarian and brain cancers.

Another recent and important Celsion Corporation (NASDAQ:CLSN) news was published by which published an article titled: “FDA Win Sends Celsion Corporation (CLSN) Shares Higher” on January 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.